# Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge

> **NCT02422121** · PHASE2 · COMPLETED · sponsor: **Revalesio Corporation** · enrollment: 30 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** RNS60
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02422121
- **Lead sponsor:** Revalesio Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422121, "Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02422121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*